The role of mean platelet volume in patients with Takayasu arteritis

Abstract

Background Takayasu arteritis is a chronic non-specific inflammatory disease and mean platelet volume can either be decreased or increased during inflammation. However, there are no published data to confirm an association between mean platelet volume and Takayasu arteritis. Our aim was to evaluate the role of mean platelet volume in patients with Takayasu arteritis. Methods A total of 119 consecutive patients with Takayasu arteritis and 217 healthy individuals were included in this study. Forty-five Takayasu arteritis patients with active disease were followed with prednisone therapy. Results Mean platelet volume of patients was low compared with control groups (10.1 ± 1.47 fL vs. 11.2 ± 0.91 fL; P < 0.001). Mean platelet volume was lower in active Takayasu arteritis than in inactive Takayasu arteritis patients (9.3 ± 1.39 fL vs. 10.6 ± 1.28 fL; P< 0.001). Mean platelet volume values were significantly increased after prednisone treatment (9.3 ± 1.45 fL vs. 10.5 ± 1.29 fL; P < 0.001). Mean platelet volume negatively correlated with C-reactive protein, erythrocyte sedimentation rate, neutrophil count and platelet count (r = - 0.219, P = 0.018; r = - 0.296, P < 0.001; r = - 0.273, P = 0.003; r =-0.486, P< 0.001), and positively correlated with platelet distribution width (r=0.304, P ≤ 0.001) in patients with Takayasu arteritis. An inverse correlation between mean platelet volume and erythrocyte sedimentation rate was observed in active Takayasu arteritis patients (r = -0.406, P = 0.010). In multiple linear regression analysis, mean platelet volume was independently correlated with erythrocyte sedimentation rate in patients with Takayasu arteritis. Conclusions Our results suggest that mean platelet volume may identify active disease in patients with Takayasu arteritis, and the values of mean platelet volume may help to establish remission of active disease after treatment in Takayasu arteritis patients.

The C-Reactive Protein/Albumin Ratio and Complete Blood Count Parameters as Indicators of Disease Activity in Patients with Takayasu Arteritis

“…However, it has previously been shown that in patients with Takayasu arteritis, the RDW, the NLR, and the PLR were increased, the MPV was decreased, and also the RDW, NLR, and PLR were shown to be positively correlated with CRP and ESR, and the MPV was negatively correlated with CRP and ESR [18–20]. Also, the NLR, PLR, RDW, and MPV have been reported to be associated with disease activity in these studies [18–20]. These previous findings support the results of the present study, but this study also showed that the MPV values were correlated with disease activity.…”

Misunderstandings Between Platelets and Neutrophils Build in Chronic Inflammation

“…Mean platelet volume (MPV) is a variable provided in the context of blood count, significantly susceptible to the effects of multiple confounders at the analytical and preanalytical level. Altered MPV has been detected in SLE, RA, large- and small-vessel vasculitides, systemic sclerosis (SSc) and chronic spontaneous urticaria (103, 104, 117, 118, 123, 129, 135, 136, 160). However, disease activity in these settings has been associated with high and low MPV values, preventing a straightforward translation of this laboratory tool into clinical practice (161).…”

“…In large vessel-vasculitides, activation of platelets may contribute to promote vascular remodeling through the release of signals, such as VEGF (206). Platelets in large-vessel vasculitides show signs of activation (129, 201), and in giant cell arteritis are significantly increased in number during active disease (147) and form hetero-aggregates with leukocytes, possibly contributing to exacerbate ischemic risk (132, 201). This evidence provides a rationale for the use of aspirin in primary prevention (207) and for the employment of platelets as diagnostic surrogates (126).…”

Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosis

“…Most of analyzed patients in that study had ET and were treated with anagrelide, a drug with a pronounced effect on MPV [22,36] that is not commonly used in myelofibrosis. Data regarding corticosteroids and MPV are limited and difficult to interpret due to different disease contexts and concomitant therapies (changes in MPV were reported in both directions [37,38]) and cannot be reasonably extrapolated to myelofibrosis setting. Systematic data regarding ruxolitinib, other JAK inhibitors, and other drug classes like immunomodulatory drugs are lacking.…”